IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Jaume Pons

APPLICATION NO.: 10/584,443 : Examiner: Virginia Lirby

FILING DATE: June 21, 2006 : Group Art Unit: 1643

TITLE: AGONIST ANTI-trkC ANTIBODIES AND

METHODS USING SAME

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Sir:

In response to the Notification of Defective Response under 35 U.S.C. 371 in the United States Designated/Elected Office mailed January 22, 2008, Applicant submits herewith the following:

- A copy of the Sequence Listing in computer readable form in compliance with the requirements of 37 CFR 1.822 and/or 1.823.
- Statement that the content of the sequence listing information in the computer readable form is identical to the written sequence listing, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).
- Petition for Extension of Time.

The Office is authorized to debit Account No. 16-1445 in payment of the outstanding fees including:

- Additional claim fees of \$420.00 for a large entity
- The fee of \$2,230.00 for five months extension of time.

Respectfully submitted,

Attorney for the Applicant Reg. No. 32,174

Pfizer Inc. Patent Department

Eastern Point Road MS8260-1611

Date: Jy 15, 2018

Groton, CT 06340 Telephone: (860)715-0081